New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 3, 2013
09:10 EDTBIIB, KSS, JWN, GPS, MLNX, SPWR, ROST, LTD, TGT, FDOOn The Fly: Pre-market Movers
HIGHER AFTER SSS REPORTS: Ross Stores (ROST), up 5.1%... Nordstrom (JWN), up 3.5%... Target (TGT), up 2.9%... ALSO HIGHER: Gap (GPS), up 4% after report of December SSS up 5%, along with $1B stock-buyback plan and deal to buy Intermix for $130M... SunPower (SPWR), up 15.5% after upgrade to Buy at Lazard Capital... LOWER AFTER EARNINGS: Family Dollar (FDO), down 9.6%... LOWER AFTER SSS REPORTS: Limited (LTD), down 5%... Kohl's (KSS), down 2.4%... ALSO LOWER: Melanox (MLNX), down 18.6% after Q4 revenue warning prompts numerous price target cuts around Street... Biogen Idec (BIIB), down 5.4% after ALS drug misses endpoint, development discontinued.
News For GPS;FDO;ROST;JWN;TGT;SPWR;KSS;LTD;MLNX;BIIB From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
July 22, 2015
16:14 EDTMLNXMellanox reports Q2 EPS 75c, consensus 62c
Subscribe for More Information
10:59 EDTBIIBBiogen drops after reporting data on Alzheimer's drug
The shares of Biogen (BIIB) are falling after the company released data on its Alzheimer's treatment candidate, aducanumab. Peer Eli Lilly (LLY) also reported data this morning on its own experimental Alzheimer's drug, solanezumab. BIOGEN: Biogen's data "does not inspire confidence," Piper analyst Joshua Schimmer wrote in a note to investors today. The 6 mg dose of the drug performed similarly to the 1mg dose, and was barely better than the placebo, the analyst stated. The cognitive and functional performance of the patients who took the 6 mg dose did not improve by a statistically significant amount, while the results of patients taking the other doses were "noisy,"Schimmer stated. Additionally, indications of excess fluid in the brain was observed in a significant number of patients, representing an additional problem for the treatment, the analyst believes. The data "is far from inspiring confidence" and makes the outlook for aducanumab "more speculative than ever," Schimmer contended. LILLY: Also this morning, Eli Lilly presented results from a pre-specified secondary analysis of several Phase 3 studies at the Alzheimer's Association International Conference. According to the company, the results suggest the treatment effect of solanezumab was preserved within a pre-specified amount in patients with mild Alzheimer's disease who received solanezumab earlier in the disease compared to patients who began treatment at a later point. Treatment differences in cognition and function between early-start and delayed-start groups at the end of the placebo-controlled period were preserved at the primary time point of 108 weeks within a pre-defined margin. Treatment differences in cognition and function between early-start and delayed-start groups at the end of the placebo-controlled period were also preserved at an additional time point of 132 weeks within a pre-defined margin.The differences at 108 weeks and at at 132 weeks remained statistically significant, the company said. PRICE ACTION: In morning trading, Biogen fell 3% to $397.43 while Eli Lilly shares rose 0.6% to $86.11.
10:01 EDTBIIBOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:28 EDTBIIBBiogen downgraded to Neutral at Piper Jaffray after Alzheimer's data
Subscribe for More Information
09:22 EDTBIIBBiogen downgraded to Neutral from Overweight at Piper Jaffray
Subscribe for More Information
09:07 EDTBIIBOn The Fly: Pre-market Movers
Subscribe for More Information
08:38 EDTJWN, TGT, KSSNRF cuts 2015 retail sales growth forecast to 3.5% from 4.1%
Subscribe for More Information
08:13 EDTSPWRDominion and SunPower partner to supply solar power to New Jersey homeowners
Dominion (D) subsidiary Dominion Retail and SunPower (SPWR) announced a collaboration of the two companies to offer SunPower solar power systems to New Jersey homeowners. Dominion will provide program details to residents through a marketing campaign scheduled to begin this summer.
07:19 EDTBIIBBiogen drops 4.8% to $390 after reporting Alzheimer's drug data
06:50 EDTBIIBBiogen's Alzheimer's candidate shows reduction of clinical decline
Subscribe for More Information
July 21, 2015
06:24 EDTBIIBPiper expects 'stronger, bolder' move from Biogen
Subscribe for More Information
06:12 EDTBIIBBiogen implied volatility of 50 at upper end of index
06:07 EDTGPSONUG: Yahoo hires VP of global network from Symantec
Subscribe for More Information
July 20, 2015
13:46 EDTTGTAmazon seen eclipsing Macy's as top U.S. clothing retailer
Subscribe for More Information
08:35 EDTROSTRoss Stores to open 27 new locations in July
Subscribe for More Information
07:32 EDTBIIBAlzheimer's Association to hold a conference
Subscribe for More Information
July 19, 2015
18:13 EDTTGTMacy's considered, rejected sale/lease-backs in past, WSJ says
Macy's (M) executives have considered sale/lease-backs "over the years" and have come to negative conclusions, reports the Wall Street Journal, citing people familiar with the company. The report comes in the wake of Starboard Value pressuring Macy's to spin off its real estate, and sources said the activist investor sees several options, including a REIT, a Hudsonís Bayís-style real estate partnership, a sale/lease-back, or borrowing money against the properties. Separately, a source said Target (T) is still reluctant to relinquish control over its real estate. Reference Link
July 16, 2015
08:17 EDTSPWRPullback in solar space provides attractive entry point, says Cowen
Subscribe for More Information
07:24 EDTMLNXMellanox should deliver beat and raise results, says Stifel
Subscribe for More Information
July 15, 2015
07:58 EDTBIIBAnalysts break down impact of $7.2B Receptos buyout
After Celgene (CELG) announced last night that the company has agreed to acquire Receptos (RCPT) for $232 per share in cash, or a total of about $7.2B net of cash acquired, research firms have chimed in with their opinions on how the proposed deal may impact others in the biotech space. Receptos key asset is Ozanimod, which is being studied in Phase III trials for relapsing multiple sclerosis and ulcerative colitis. DERIVATIVE CALLS: Piper Jaffray analyst Edward Tenthoff told investors that he views Celgene's deal for Receptos as good for Arena Pharmaceuticals (ARNA). The analyst notes that Arena's APD334 is already showing dose-dependent decreases in circulating lymphocyte counts and that the company will initiate Phase II studies in ulcerative colitis and Crohn's disease this year. Tenthoff reiterates an Overweight rating and $7.50 price target on Arena, which has a market capitalization around $1B and closed yesterday up 8c to $4.47. In its own note to investors this morning, Nomura said Celgene's deal could put downward pressure on Biogen's (BIIB) long-term multiple sclerosis estimates. Nomura's M. Ian Somaiya contended that one-year Phase II efficacy data for Ozanimod looked as good as Novartisís (NVS) Gilenya and Biogen's Tecfideraís Phase III at year 2. Somaiya also wondered if rival Gilead (GILD) could be "looking for something bigger" than Receptos for its own deal, telling investors that the firm views Incyte (INCY) as Gilead's most likely takeout target. Incyte's shares closed up $4.46 at $117.46 yesterday, giving the company a market cap of about $20B. RIVAL BID?: Wedbush analyst Liana Moussatos believes another bidder may seek to acquire Receptos, noting that she previously estimated Receptos could be valued at $348 per share, or about $10.9B, in a buyout. Moussatos noted that Celgene said it expects annual peak sales for Ozanimod to reach about $4B-$6B for RMS and UC, making its acquisition price of $7.2BN only a bit more than about 1X peak sales without accounting for other possible indications or the rest of its pipeline. Moussatos told investors she sees "plenty" of potential upside to justify a rival bidder stepping in and reiterated the firm's Outperform rating on Receptos shares. PRICE ACTION: In pre-market trading, Receptos rose 10% to $228.61 while Gilead gained 1.4% to about $119 per share.
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use